HCM
CADX

Highbridge Capital Management’s CADENCE PHARMACEUTICALS, INC COM STK CADX Stock Holding History

Highbridge Capital Management’s Portfolio CADX Stock Details CADX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-20,869
Closed -$142K – 1688
2013
Q2 		$142K Buy
+20,869
New +$145K ﹤0.01% 1223

Other funds holding CADX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
CPCM
Clifton Park Capital Management Wilmington, Delaware $881M AUM 5.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Highbridge Capital Management's CADX Position: Q3 2013 in Review

Highbridge Capital Management sold out of CADENCE PHARMACEUTICALS, INC COM STK (CADX) in Q3 2013, closing a stake of 20,869 shares — an estimated $142K sold.

Highbridge Capital Management first reported a position in CADX in Q2 2013 and held it in 1 quarter. The position peaked at $142K in Q2 2013. 90 funds tracked by Wall St. Rank hold CADX as of Q3 2013.

  • Highbridge Capital Management reported no remaining CADENCE PHARMACEUTICALS, INC COM STK position as of Q3 2013 after selling out during the quarter.
  • Highbridge Capital Management sold 20,869 CADENCE PHARMACEUTICALS, INC COM STK shares in Q3 2013, an estimated $142K.
  • Highbridge Capital Management first reported a position in CADENCE PHARMACEUTICALS, INC COM STK in Q2 2013 and held it in 1 quarter.
  • Highbridge Capital Management's CADENCE PHARMACEUTICALS, INC COM STK position peaked at $142K in Q2 2013.
  • 90 funds tracked by Wall St. Rank held CADENCE PHARMACEUTICALS, INC COM STK as of Q3 2013.

Based on Highbridge Capital Management's 13F filing for Q3 2013, filed 14 Nov 2013.